A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer.

Trial Profile

A Phase I Dose-Escalation Trial of Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab Following Cytoreduction in Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Jul 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Adenocarcinoma; Appendiceal cancer; Cancer metastases; Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jul 2018 Planned End Date changed from 31 Jan 2019 to 30 Sep 2019.
    • 06 Jul 2018 Planned primary completion date changed from 31 May 2018 to 30 Sep 2019.
    • 20 Jan 2018 Results (n=18) presented at the 2018 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top